Custom synthesis | Naphthyridine | Pyrimidine | Indoline |
Antineoplastics

Cisplatin 15663-27-1

Cisplatin 15663-27-1

Cisplatin, cisplatinum, platamin, neoplatin, cismaplat or cis-diamminedichloroplatinum(II) (CDDP) is a chemotherapy drug. It was the first member of a class of platinum-containing anti-cancer drugs, which now also includes carboplatin and oxaliplatin. These platinum complexes react in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death).
 
It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.

Cisplatin is administered intravenously as short-term infusion in normal saline for treatment of solid malignancies. It is used to treat various types of cancers, including sarcomas, some carcinomas (e.g., small cell lung cancer, and ovarian cancer), lymphomas, bladder cancer, cervical cancer,[5] and germ cell tumors.
 
Cisplatin is particularly effective against testicular cancer; the cure rate was improved from 10% to 85%.
 
In addition, cisplatin is used in Auger therapy.

Cisplatin 15663-27-1
Appearance: Yellow powder
Cas No:15663-27-1
EINECS:239-733-8
Formula:Cl2H6N2Pt
Molecular Weight:300.05
Melting Point:340 °C
Boiling Point:NA
Flash Point: NA
Usage:Antineoplastics

GMP for Cisplatin 15663-27-1 is available, DMF for Cisplatin 15663-27-1 can be provided against commercial order quantity.
 
Disclaimer:Those products (Cisplatin 15663-27-1) patented are for lab analytical & research purposes only.